Fig. 3
From: KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
MRTX1257 increases the efficacy of RT in immunocompetent BALB/c mice bearing CT26 KRASG12C+/+ tumors and achieved durable responses in association with RT. A BALB/c mice were subcutaneously inoculated with CT26 KRASG12C+/+ cells. Once the tumors reached an average volume of 90–100 mm3, mice received via oral administration 50 mg/kg of MRTX1257 or vehicle. The day after, mice received a single fraction of 6 Gy on the tumor mass. MRTX1257 at the dose of 50 mg/kg or vehicle were then administered at D1 and D3 after RT. The experiment was repeated twice. B Tumor growth (mean ± SEM). **: p < 0.01; ***: p < 0.001; ****: p < 0.0001 (two-way ANOVA). (C) Mean tumor volumes in each group 10 days after RT are represented. **: p < 0.01; ***: p < 0.001; ****: p < 0.0001 (one-way ANOVA). D Individual growth profiles of CT26 KRAS G12C+/+ tumors are represented for each condition. The number of mice achieving durable response with no tumor being assessed at the end of the experiment is indicated below each panel. E Survival Kaplan–Meier curves were compared between each group using the log-rank test. *: p < 0.05; **: p < 0.01; ****: p < 0.0001. F Immunocompetent BALB/c mice bearing CT26 KRASG12C+/+ tumors and cured by the combination of RT and MRTX1257 were subsequently rechallenged with either 1.106 CT26 KRASG12C+/+ (top) or 5.105 CT26 WT cells (bottom) subcutaneously injected in their contralateral flank. Their survivals were then compared with those of naive mice receiving similar injections